• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型速效有效口服抗疟药CGP 56697在中国进行的治疗恶性疟原虫疟疾的II期试验。

Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria.

作者信息

Jiao X, Liu G Y, Shan C O, Zhao X, Li X W, Gathmann I, Royce C

机构信息

Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS), Beijing, People's Republic of China.

出版信息

Southeast Asian J Trop Med Public Health. 1997 Sep;28(3):476-81.

PMID:9561595
Abstract

One hundred and two Chinese out-patients with naturally acquired, previously untreated, falciparum malaria were selected to evaluate the efficacy of a new combination anti-malaria therapy, CGP 56697 (artemether plus benflumetol). In this open non-comparative trial each patient received a combination of 80 mg artemether and 480 mg benflumetol given orally at 0, 8, 24 and 48 hours (total: 320 mg artemether, 1,920 mg benflumetol). Patients were kept for 28 days in a transmission-free hospital in an area with chloroquine resistant falciparum malaria to prevent reinfection and to aid diagnosis of recrudescence. Progress and possible adverse effects were monitored by blood film parasitology, blood biochemistry assays, urinalysis, ECG and X-ray. Ninety-eight of the 102 patients were shown to be free of infection at 28 days, a 96.1% cure rate. Parasite reduction at 24 hours was 99.4%. Time to effect complete parasite clearance ranged from 24 to 54 hours (median 30 hours). Time for fever clearance ranged from 6 to 78 hours (median 18 hours). Recrudescence was low (3.9%). No significant adverse side-effects were encountered. It is concluded that CGP 56697, a combination anti-malaria therapy of artemether with benflumetol, offered a rapid and highly effective treatment for acute uncomplicated falciparum malaria in an area of chloroquine-resistant malaria in China.

摘要

选取102例自然感染、未经治疗的恶性疟中国门诊患者,以评估新型抗疟联合疗法CGP 56697(蒿甲醚加本芴醇)的疗效。在这项开放性非对照试验中,每位患者在0、8、24和48小时口服80毫克蒿甲醚和480毫克本芴醇的组合(总计:320毫克蒿甲醚,1920毫克本芴醇)。患者在一个存在对氯喹耐药恶性疟的地区的无疟疾传播医院中留观28天,以预防再次感染并协助诊断复发情况。通过血片寄生虫学检查、血液生化检测、尿液分析、心电图和X光检查来监测病情进展和可能出现的不良反应。102例患者中有98例在28天时显示无感染,治愈率为96.1%。24小时时的寄生虫减少率为99.4%。完全清除寄生虫的时间为24至54小时(中位数为30小时)。退热时间为6至78小时(中位数为18小时)。复发率较低(3.9%)。未出现明显的不良副作用。结论是,蒿甲醚与本芴醇的抗疟联合疗法CGP 56697为中国氯喹耐药疟疾地区的急性非复杂性恶性疟提供了快速且高效的治疗方法。

相似文献

1
Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria.新型速效有效口服抗疟药CGP 56697在中国进行的治疗恶性疟原虫疟疾的II期试验。
Southeast Asian J Trop Med Public Health. 1997 Sep;28(3):476-81.
2
Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria.青蒿琥酯口服制剂与奎宁加四环素治疗急性非复杂性恶性疟的比较。
Bull World Health Organ. 1994;72(2):233-8.
3
Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.在老挝人民民主共和国,氯喹加周效磺胺-乙胺嘧啶与青蒿琥酯加甲氟喹以及蒿甲醚-本芴醇治疗非复杂性恶性疟的随机对照研究
Clin Infect Dis. 2004 Oct 15;39(8):1139-47. doi: 10.1086/424512. Epub 2004 Sep 27.
4
A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India.印度一项关于口服蒿甲醚与口服氯喹治疗成人急性非复杂性恶性疟原虫疟疾的随机、双盲、平行组、比较安全性和疗效试验。
Am J Trop Med Hyg. 2000 Mar;62(3):402-8. doi: 10.4269/ajtmh.2000.62.402.
5
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.
Trop Med Int Health. 1998 Jun;3(6):498-504. doi: 10.1046/j.1365-3156.1998.00250.x.
6
The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France.
Int J Antimicrob Agents. 1999 Jul;12(2):159-69. doi: 10.1016/s0924-8579(99)00070-9.
7
Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria.蒿甲醚-乙胺嘧啶治疗耐乙胺嘧啶恶性疟
Southeast Asian J Trop Med Public Health. 1996 Mar;27(1):19-23.
8
A comparative study of the schizontocidal efficacy and safety of artemether versus chloroquine in uncomplicated malaria.蒿甲醚与氯喹治疗非复杂性疟疾的裂殖体杀灭疗效及安全性的比较研究。
Cent Afr J Med. 1992 Jul;38(7):257-63.
9
Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria.在泰国非复杂性恶性疟患者中,以蒿甲醚-本芴醇固定复方制剂(CGP 56697)形式给予的本芴醇的药代动力学。
Int J Clin Pharmacol Res. 1999;19(2):41-6.
10
Efficacy of artemether-lumefantrine treatment in patients with acute uncomplicated Falciparum malaria in Mayotte, a French collectivity of the Comoros Archipelago.蒿甲醚-本芴醇治疗科摩罗群岛法国海外领地马约特岛急性非复杂性恶性疟患者的疗效。
Parasite. 2004 Sep;11(3):325-8.

引用本文的文献

1
The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.剂量对蒿甲醚-本芴醇抗疟疗效的影响:个体患者数据的系统评价与汇总分析
Lancet Infect Dis. 2015 Jun;15(6):692-702. doi: 10.1016/S1473-3099(15)70024-1. Epub 2015 Mar 16.
2
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs.一项在健康志愿者中诱导血期疟原虫感染以测试新抗疟药物疗效的初步随机试验。
PLoS One. 2011;6(8):e21914. doi: 10.1371/journal.pone.0021914. Epub 2011 Aug 22.
3
Coartem: the journey to the clinic.
科泰复:走向临床。
Malar J. 2009 Oct 12;8 Suppl 1(Suppl 1):S3. doi: 10.1186/1475-2875-8-S1-S3.
4
Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.蒿甲醚-本芴醇治疗尼日利亚婴幼儿急性非复杂性恶性疟的疗效和安全性评估。
Malar J. 2008 Nov 27;7:246. doi: 10.1186/1475-2875-7-246.
5
Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand.去丁基-本芴醇,一种新型抗疟化合物:对来自泰国的恶性疟原虫新鲜分离株的体外活性
Antimicrob Agents Chemother. 2001 Jul;45(7):2106-9. doi: 10.1128/AAC.45.7.2106-2109.2001.
6
In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether.恶性疟原虫的体外敏感性以及对双氢青蒿素哌喹(本芴醇)和蒿甲醚的临床反应。
Br J Clin Pharmacol. 2000 May;49(5):437-44. doi: 10.1046/j.1365-2125.2000.00176.x.
7
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.蒿甲醚-本芴醇的临床药代动力学与药效学
Clin Pharmacokinet. 1999 Aug;37(2):105-25. doi: 10.2165/00003088-199937020-00002.
8
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs.与标准抗疟药物相比,本芴醇对158株塞内加尔恶性疟原虫分离株的体外活性。
Antimicrob Agents Chemother. 1999 Feb;43(2):418-20. doi: 10.1128/AAC.43.2.418.
9
In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon.咯萘啶(本芴醇)对喀麦隆雅温得恶性疟原虫临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Sep;42(9):2347-51. doi: 10.1128/AAC.42.9.2347.